(Q39626084)

13 September 2017

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser (English)

1 reference

13 September 2017

1 reference

Y M Cho

1

1 reference

PubMed ID

21116606

13 September 2017

T J Kieffer

series ordinal

2

1 reference

13 September 2017

30 November 2010

1 reference

13 September 2017

1 reference

13 September 2017

54

1 reference

13 September 2017

2

1 reference

13 September 2017

219-222

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-010-1986-3

13 September 2017

0 references

cites work

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

21 January 2018

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Normalization of metabolic syndrome using fenofibrate, metformin or their combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-010-1986-3

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

21 January 2018

1 reference

12 December 2020

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

12 December 2020

A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells

1 reference

12 December 2020

10.1007/S00125-010-1986-3

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

21116606